In vivo modulation of CYP enzymes by quinidine and rifampin

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 401-411

  Branch, Robert A ^a   Adedoyin, Adedayo ^a   Frye, Reginald F ^a   Wilson, John W ^a   Romkes, Marjorie ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DAPSONE; DEBRISOQUINE; MEPHENYTOIN; QUINIDINE; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACETYLATION; DRUG METABOLISM; DRUG MIXTURE; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; OXIDATION; PRIORITY JOURNAL;

ACETYLATION; ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; DEBRISOQUIN; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; QUINIDINE; REFERENCE VALUES; RIFAMPIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; THEOPHYLLINE;

EID: 0033736113     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110561     Document Type: Article

References (54)

1. Metabolic activation of carcinogens
2. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s
3. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy
4. Cytochrome P-450 and its role in drug metabolism
5. Human cytochromes P-450
6. P450 Genes: Structure, evolution, and regulation
7. Evolution of the P450 gene superfamily
8. Substrate specificities and functions of the P450 cytochromes
9. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
10. Human cytochromes P450: Problems and prospects
11. Cytochrome P-450 enzymes and drug metabolism
12. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients
13. Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6
14. Increased susceptibility to carbon tetrachloride poisoning in the rat after pretreatment with oral phenobarbitone
15. Role of detoxifying enzymes in bromobenzene-induced liver necrosis
16. Disulfiram prevents acetaminophen hepatotoxicity in rats
17. Concepts in causality: Chemically induced human bladder cancer
18. N-acetylation pharmacogenetics
19. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors
20. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer
21. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer
22. Environmental procarcinogen hypothesis of bladder cancer in man: Dapsone hydroxylation as a susceptibility risk factor for bladder cancer
23. Quinidine: Potent inhibition of sparteine and debrisoquine oxidation in vivo
24. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine
25. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans
26. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
27. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
28. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
29. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450111A induction
30. The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine J Pharm Biomed Anal
31. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
32. Identification of rifampin-inducible P450111A4 (CYP3A4) in human small bowel enterocytes
33. The influence of rifampin treatment on caffeine clearance in healthy man
34. Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers
35. Theophylline-rifampicin interaction: Non-selective induction of theophylline metabolic pathways
36. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose
37. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin
38. The influence of enzyme induction on polymorphic sparteine oxidation
39. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes
40. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
41. Evidence that CYP2C19 is the major S-mephenytoin 4'-hydroxylase enzyme in humans
42. Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
43. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4
44. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo
45. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity
46. The polymorphic acetylation of dapsone in man
47. The major defect responsible for the polymorphism of S-mephenytion metabolism in humans
48. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
49. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility
50. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African Americans
51. Primary human hepatocytes as a tool for the evaluation of structure activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentive and rifabutin
52. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: Investigation with selective metabolic probes
53. Chloroquine modulation of specific metabolizing enzymes activities: Investigation with selective five drug cocktail